IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-α-mediated bone loss

Journal of Immunology

Volumn 186, Issue 11, 2011, Pages 6097-6105

  Zaiss, Mario M ^a   Kurowska Stolarska, Mariola ^b   Böhm, Christina ^a   Gary, Regina ^a   Scholtysek, Carina ^a   Stolarski, Bartosz ^b   Reilly, James ^b   Kerr, Shauna ^b   Millar, Neal L ^b   Kamradt, Thomas ^c   McInnes, Iain B ^b   Fallon, Padraic G ^d   David, Jean Pierre ^a   Liew, Foo Y ^b   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR ANTIBODY; INTERLEUKIN 4; MONOCLONAL ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 33; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOCRINE EFFECT; BONE TURNOVER; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CHONDROCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOCLASTS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958073057     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003487     Document Type: Article

References (44)

1. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490. (Pubitemid 41587888)
2. Liew, F. Y., N. I. Pitman, and I. B. McInnes. 2010. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10: 103-110.
3. Moussion, C., N. Ortega, and J. P. Girard. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 3: e3331.
4. Carriere, V., L. Roussel, N. Ortega, D. A. Lacorre, L. Americh, L. Aguilar, G. Bouche, and J. P. Girard. 2007. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104: 282-287.
5. Townsend, M. J., P. G. Fallon, D. J. Matthews, H. E. Jolin, and A. N. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191: 1069-1076.
6. Hoshino, K., S. Kashiwamura, K. Kuribayashi, T. Kodama, T. Tsujimura, K. Nakanishi, T. Matsuyama, K. Takeda, and S. Akira. 1999. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190: 1541-1548.
7. Senn, K. A., K. D. McCoy, K. J. Maloy, G. Stark, E. Fröhli, T. Rülicke, and R. Klemenz. 2000. T1-deficient and T1-Fc-transgenic mice develop a normal protective Th2-type immune response following infection with Nippostrongylus brasiliensis. Eur. J. Immunol. 30: 1929-1938.
8. Suzukawa, M., M. Iikura, R. Koketsu, H. Nagase, C. Tamura, A. Komiya, S. Nakae, K. Matsushima, K. Ohta, K. Yamamoto, and M. Yamaguchi. 2008. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181: 5981-5989.
9. Pecaric-Petkovic, T., S. A. Didichenko, S. Kaempfer, N. Spiegl, and C. A. Dahinden. 2009. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113: 1526-1534.
10. Ho, L. H., T. Ohno, K. Oboki, N. Kajiwara, H. Suto, M. Iikura, Y. Okayama, S. Akira, H. Saito, S. J. Galli, and S. Nakae. 2007. IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc{varepsilon}RI signals. J. Leukoc. Biol. 82: 1481-1490.
11. Kondo, Y., T. Yoshimoto, K. Yasuda, S. Futatsugi-Yumikura, M. Morimoto, N. Hayashi, T. Hoshino, J. Fujimoto, and K. Nakanishi. 2008. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20: 791-800.
12. Kurowska-Stolarska, M., P. Kewin, G. Murphy, R. C. Russo, B. Stolarski, C. C. Garcia, M. Komai-Koma, N. Pitman, Y. Li, W. Niedbala, et al. 2008. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. [Published erratum appears in 2008 J. Immunol. 181: 8170.] J. Immunol. 181: 4780-4790.
13. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5: 373-379.
14. Rank, M. A., T. Kobayashi, H. Kozaki, K. R. Bartemes, D. L. Squillace, and H. Kita. 2009. IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123: 1047-1054.
15. Chackerian, A. A., E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelein. 2007. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179: 2551-2555.
16. Komai-Koma, M., D. Xu, Y. Li, A. N. McKenzie, I. B. McInnes, and F. Y. Liew. 2007. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37: 2779-2786.
17. Schneider, E., A. F. Petit-Bertron, R. Bricard, M. Levasseur, A. Ramadan, J. P. Girard, A. Herbelin, and M. Dy. 2009. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J. Immunol. 183: 3591-3597.
18. Pushparaj, P. N., H. K. Tay, S. C. H'ng, N. Pitman, D. Xu, A. McKenzie, F. Y. Liew, and A. J. Melendez. 2009. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. USA 106: 9773-9778.
19. Stolarski, B., M. Kurowska-Stolarska, P. Kewin, D. Xu, and F. Y. Liew. 2010. IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 185: 3472-3480.
20. Kurowska-Stolarska, M., B. Stolarski, P. Kewin, G. Murphy, C. J. Corrigan, S. Ying, N. Pitman, A. Mirchandani, B. Rana, N. van Rooijen, et al. 2009. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183: 6469-6477.
21. Alves-Filho, J. C., F. Sônego, F. O. Souto, A. Freitas, W. A. Verri, Jr., M. Auxiliadora-Martins, A. Basile-Filho, A. N. McKenzie, D. Xu, F. Q. Cunha, and F. Y. Liew. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16: 708-712.
22. Xu, D., H. R. Jiang, P. Kewin, Y. Li, R. Mu, A. R. Fraser, N. Pitman, M. Kurowska-Stolarska, A. N. McKenzie, I. B. McInnes, and F. Y. Liew. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 105: 10913-10918.
23. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
24. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442.
25. Wei, S., H. Kitaura, P. Zhou, F. P. Ross, and S. L. Teitelbaum. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115: 282-290.
26. Zwerina, J., K. Redlich, K. Polzer, L. Joosten, G. Krönke, J. Distler, A. Hess, N. Pundt, T. Pap, O. Hoffmann, et al. 2007. TNF-induced structural joint damage is mediated by IL-1. Proc. Natl. Acad. Sci. USA 104: 11742-11747.
27. Horwood, N. J., N. Udagawa, J. Elliott, D. Grail, H. Okamura, M. Kurimoto, A. R. Dunn, T. Martin, and M. T. Gillespie. 1998. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 101: 595-603.
28. Udagawa, N., N. J. Horwood, J. Elliott, A. Mackay, J. Owens, H. Okamura, M. Kurimoto, T. J. Chambers, T. J. Martin, and M. T. Gillespie. 1997. Interleukin- 18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon- gamma to inhibit osteoclast formation. J. Exp. Med. 185: 1005-1012.
29. Schulze, J., T. Bickert, F. T. Beil, M. M. Zaiss, J. Albers, K. Wintges, T. Streichert, K. Klaetschke, J. Keller, T. N. Hissnauer, et al. 2011. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. 26: 704-717.
30. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025-4031. (Pubitemid 21905432)
31. Löhning, M., A. Stroehmann, A. J. Coyle, J. L. Grogan, S. Lin, J. C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt. 1998. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. USA 95: 6930-6935.
32. Kurowska-Stolarska, M., J. H. Distler, A. Jüngel, W. Rudnicka, E. Neumann, T. Pap, R. H. Wenger, B. A. Michel, U. Müller-Ladner, R. E. Gay, et al. 2009. Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis Rheum. 60: 3663-3675.
33. Zaiss, M. M., R. Axmann, J. Zwerina, K. Polzer, E. Gückel, A. Skapenko, H. Schulze-Koops, N. Horwood, A. Cope, and G. Schett. 2007. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 56: 4104-4112. (Pubitemid 350262338)
34. Redlich, K., S. Hayer, R. Ricci, J. P. David, M. Tohidast-Akrad, G. Kollias, G. Steiner, J. S. Smolen, E. F. Wagner, and G. Schett. 2002. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110: 1419-1427.
35. Mun, S. H., N. Y. Ko, H. S. Kim, J. W. Kim, K. Kim do, A. R. Kim, S. H. Lee, Y. G. Kim, C. K. Lee, S. H. Lee, et al. 2010. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol. Life Sci. 67: 3883-3892.
36. Saidi, S., F. Bouri, P. Lencel, L. Duplomb, M. Baud'huin, S. Delplace, D. Leterme, F. Miellot, D. Heymann, P. Hardouin, et al. 2011. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 53: 347-354.
37. Heimbeck, I., T. P. Hofer, C. Eder, A. K. Wright, M. Frankenberger, A. Marei, G. Boghdadi, J. Scherberich, and L. Ziegler-Heitbrock. 2010. Standardized single-platform assay for human monocyte subpopulations: Lower CD14+CD16 ++ monocytes in females. Cytometry A 77: 823-830.
38. Cros, J., N. Cagnard, K. Woollard, N. Patey, S. Y. Zhang, B. Senechal, A. Puel, S. K. Biswas, D. Moshous, C. Picard, et al. 2010. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33: 375-386.
39. Geissmann, F., M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley. 2010. Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
40. Palmer, G., D. Talabot-Ayer, C. Lamacchia, D. Toy, C. A. Seemayer, S. Viatte, A. Finckh, D. E. Smith, and C. Gabay. 2009. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60: 738-749.
41. Kaieda, S., K. Shin, P. A. Nigrovic, K. Seki, R. T. Lee, R. L. Stevens, and D. M. Lee. 2010. Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J. Biol. Chem. 285: 21478-21486.
42. Matsuyama, Y., H. Okazaki, H. Tamemoto, H. Kimura, Y. Kamata, K. Nagatani, T. Nagashima, M. Hayakawa, M. Iwamoto, T. Yoshio, et al. 2010. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J. Rheumatol. 37: 18-25.
43. Mu, R, H. Q. Huang, Y. H. Li, C. Li, H. Ye, and Z. G. Li. 2010. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J. Rheumatol. 37: 2006-2013.
44. Xu, D., H. R. Jiang, Y. Li, P. N. Pushparaj, M. Kurowska-Stolarska, B. P. Leung, R. Mu, H. K. Tay, A. N. McKenzie, I. B. McInnes, et al. 2010. IL-33 exacerbates autoantibody-induced arthritis. J. Immunol. 184: 2620-2626.